^
Association details:
| Biomarker: | KIT V559D |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition
Excerpt:
In vitro drug sensitivity for imatinib, dasatinib and nilotinib of Ba/F3 stable transformants expressing KITL576P and KITV559D: (a,b) proliferation inhibition, (c,d) increased apoptosis, and (e,f) decrease in KIT phosphorylation by immunoprecipitation.
DOI:
10.1002/ijc.22681
